Compare SURG & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | CASI |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 24.9M |
| IPO Year | N/A | 1996 |
| Metric | SURG | CASI |
|---|---|---|
| Price | $1.50 | $0.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.50 | $4.00 |
| AVG Volume (30 Days) | ★ 85.2K | 34.8K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,372,555.00 | $26,846,000.00 |
| Revenue This Year | $7.13 | N/A |
| Revenue Next Year | $122.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.72 |
| 52 Week Low | $1.05 | $0.80 |
| 52 Week High | $3.47 | $3.47 |
| Indicator | SURG | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 24.95 | 30.73 |
| Support Level | $1.40 | $0.80 |
| Resistance Level | $1.88 | $0.97 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 12.70 | 14.10 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.